OBJECTIVE: To determine the epidemiology of CA-125 in women without ovarian cancer. METHODS: We analyzed demographic, medical and lifestyle characteristics related to CA-125, measured using the Centocor CA-125II RIA assay, among 25,608 multi-ethnic U.S. women aged 55-74 years enrolled in a cancer screening trial and found to have no evidence of ovarian cancer. RESULTS:MeanCA-125 level was 11.9 U/ml (SD 8.3); median 10.0 U/ml, interquartile range 8.0-14.0. High levels, using the clinical cut point of >or=35 U/ml, were associated with increased age (p<0.001) and former smoking (p<0.021), while hysterectomy and obesity were protective (p<0.001). Mean levels were higher with increasing age (p<0.001), ever use of hormone therapy (p<0.001), former smoking (p<0.017) and history of breast cancer (p<0.002), but lower (p<0.001) with non-White status, previous hysterectomy, current smoking, and obesity. Current hormone therapy use was not associated with CA-125 in women without a uterus. CONCLUSION: In post-menopausal women without ovarian cancer, CA-125 level is influenced by a number of factors, including race/ethnicity, age, hysterectomy, smoking history and obesity.
RCT Entities:
OBJECTIVE: To determine the epidemiology of CA-125 in women without ovarian cancer. METHODS: We analyzed demographic, medical and lifestyle characteristics related to CA-125, measured using the Centocor CA-125II RIA assay, among 25,608 multi-ethnic U.S. women aged 55-74 years enrolled in a cancer screening trial and found to have no evidence of ovarian cancer. RESULTS: Mean CA-125 level was 11.9 U/ml (SD 8.3); median 10.0 U/ml, interquartile range 8.0-14.0. High levels, using the clinical cut point of >or=35 U/ml, were associated with increased age (p<0.001) and former smoking (p<0.021), while hysterectomy and obesity were protective (p<0.001). Mean levels were higher with increasing age (p<0.001), ever use of hormone therapy (p<0.001), former smoking (p<0.017) and history of breast cancer (p<0.002), but lower (p<0.001) with non-White status, previous hysterectomy, current smoking, and obesity. Current hormone therapy use was not associated with CA-125 in women without a uterus. CONCLUSION: In post-menopausal women without ovarian cancer, CA-125 level is influenced by a number of factors, including race/ethnicity, age, hysterectomy, smoking history and obesity.
Authors: N K Simpson; C C Johnson; S L Ogden; E Gamito; N Trocky; C McGuire; J Martin; S Barrow; L Lamerato; L M Flickinger; K G Broski; D Engelhard; C Hilke; J Bonk; B Gahagan; L H Gren; J Childs; K Lappe; M Fouad; J Thompson; D Sullivan Journal: Control Clin Trials Date: 2000-12
Authors: D K Pauler; U Menon; M McIntosh; H L Symecko; S J Skates; I J Jacobs Journal: Cancer Epidemiol Biomarkers Prev Date: 2001-05 Impact factor: 4.254
Authors: P F Pinsky; A Miller; B S Kramer; T Church; D Reding; P Prorok; E Gelmann; R E Schoen; S Buys; R B Hayes; C D Berg Journal: Am J Epidemiol Date: 2007-01-22 Impact factor: 4.897
Authors: P C Prorok; G L Andriole; R S Bresalier; S S Buys; D Chia; E D Crawford; R Fogel; E P Gelmann; F Gilbert; M A Hasson; R B Hayes; C C Johnson; J S Mandel; A Oberman; B O'Brien; M M Oken; S Rafla; D Reding; W Rutt; J L Weissfeld; L Yokochi; J K Gohagan Journal: Control Clin Trials Date: 2000-12
Authors: Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Carol Smigal; Michael J Thun Journal: CA Cancer J Clin Date: 2006 Mar-Apr Impact factor: 508.702
Authors: Lois E Lamerato; Pamela M Marcus; Gordon Jacobsen; Christine Cole Johnson Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-04 Impact factor: 4.254
Authors: Brenda B J Hermsen; Silvia von Mensdorff-Pouilly; Johannes Berkhof; Paul J van Diest; Johan J P Gille; Fred H Menko; Marinus A Blankenstein; Peter Kenemans; René H M Verheijen Journal: J Clin Oncol Date: 2007-04-10 Impact factor: 44.544
Authors: Babatunde O Akinwunmi; Ana Babic; Allison F Vitonis; Daniel W Cramer; Linda Titus; Shelley S Tworoger; Kathryn L Terry Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-09-20 Impact factor: 4.254
Authors: Naoko Sasamoto; Ana Babic; Bernard A Rosner; Renée T Fortner; Allison F Vitonis; Hidemi Yamamoto; Raina N Fichorova; Anne Tjønneland; Louise Hansen; Kim Overvad; Marina Kvaskoff; Agnès Fournier; Francesca Romana Mancini; Heiner Boeing; Antonia Trichopoulou; Eleni Peppa; Anna Karakatsani; Domenico Palli; Valeria Pala; Amalia Mattiello; Rosario Tumino; Chiara C Grasso; N Charlotte Onland-Moret; Elisabete Weiderpass; J Ramón Quirós; Leila Lujan-Barroso; Miguel Rodríguez-Barranco; Sandra Colorado-Yohar; Aurelio Barricarte; Miren Dorronsoro; Annika Idahl; Eva Lundin; Hanna Sartor; Kay-Tee Khaw; Timothy J Key; David Muller; Elio Riboli; Marc J Gunter; Laure Dossus; Rudolf Kaaks; Daniel W Cramer; Shelley S Tworoger; Kathryn L Terry Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-04-04 Impact factor: 4.254
Authors: Nicole Urban; Jason D Thorpe; Lindsay A Bergan; Robin M Forrest; Archana V Kampani; Nathalie Scholler; Kathy C O'Briant; Garnet L Anderson; Daniel W Cramer; Christine D Berg; Martin W McIntosh; Patricia Hartge; Charles W Drescher Journal: J Natl Cancer Inst Date: 2011-09-14 Impact factor: 13.506
Authors: Jian-Lun Xu; John Commins; Edward Partridge; Thomas L Riley; Philip C Prorok; Christine C Johnson; Saundra S Buys Journal: Gynecol Oncol Date: 2011-12-22 Impact factor: 5.482
Authors: Jennifer M Watson; Photini F Rice; Samuel L Marion; Molly A Brewer; John R Davis; Jeffrey J Rodriguez; Urs Utzinger; Patricia B Hoyer; Jennifer K Barton Journal: J Biomed Opt Date: 2012-07 Impact factor: 3.170
Authors: Weston A Welge; Andrew T DeMarco; Jennifer M Watson; Photini S Rice; Jennifer K Barton; Matthew A Kupinski Journal: J Med Imaging (Bellingham) Date: 2014-07-18
Authors: Tracey Edgell; G Martin-Roussety; G Barker; D J Autelitano; D Allen; P Grant; G E Rice Journal: J Cancer Res Clin Oncol Date: 2010-01-16 Impact factor: 4.553